Page last updated: 2024-08-26

terameprocol and Disease Exacerbation

terameprocol has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Desideri, S; Grossman, SA; Mikkelsen, T; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X1
Ashfaq, R; Bernstein, HS; Brock, M; Deasel, M; Dhara, S; Forastiere, A; Hansel, DE; Harmon, J; Huang, RC; Maitra, A; Montgomery, E; Shimada, Y; Washington, MK1

Trials

1 trial(s) available for terameprocol and Disease Exacerbation

ArticleYear
Phase I study of terameprocol in patients with recurrent high-grade glioma.
    Neuro-oncology, 2012, Volume: 14, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Masoprocol; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome

2012

Other Studies

1 other study(ies) available for terameprocol and Disease Exacerbation

ArticleYear
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
    The American journal of surgical pathology, 2005, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis

2005